The high market-implied probability of no new pandemic in 2026 reflects the absence of any novel pathogen exhibiting sustained human-to-human transmission with pandemic-scale potential, according to CDC and WHO surveillance data through mid-May. Respiratory activity remains low nationally, with COVID-19 infections declining in most states and the 2025-2026 influenza season following expected seasonal patterns driven by subclade K H3N2 viruses rather than a divergent strain capable of immune escape. Ongoing monitoring of avian influenza H5N1 and other zoonotic threats shows limited spillover without widespread adaptation, while global preparedness enhancements—including updated WHO pandemic agreements and CDC laboratory capacity—bolster early detection and containment. Historical precedents of rapid escalation are absent in current epidemiological indicators, leaving little near-term catalyst for market odds to shift.